Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate

ClinicalTrials.gov ID: NCT00369928

Public ClinicalTrials.gov record NCT00369928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 mg Twice Daily and 100 mg Twice Daily, of PG-760564 in Adult Patients With RA Receiving Methotrexate

Study identification

NCT ID: NCT00369928
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Procter and Gamble; Industry
Enrollment: 254 participants

Conditions and interventions

Conditions

Rheumatoid Arthritis

Interventions

PG-760564 Drug
Placebo dose Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2006
Primary completion: Dec 31, 2007
Completion: Dec 31, 2007
Last update posted: Sep 7, 2011

2006 – 2008

United States locations

U.S. sites: 24
U.S. states: 13
U.S. cities: 23

Facility	City	State	ZIP	Site status
Research Facility	Hot Springs	Arkansas	71913	—
Research Facility	Beverly Hills	California	90211	—
Research Facility	Mission Viejo	California	92691	—
Research Facility	Chiefland	Florida	32626	—
Research Facility	Dunedin	Florida	34698	—
Research Facility	Fort Lauderdale	Florida	33334	—
Research Facility	Tavares	Florida	32778	—
Research Facility	Decatur	Georgia	30033	—
Research Facility	Marietta	Georgia	30060	—
Research Facility	Rome	Georgia	30165	—
Research Facility	Meridian	Idaho	83642	—
Research Facility	New Orleans	Louisiana	70121	—
Research Facility	Omaha	Nebraska	68134	—
Research Facility	Elizabeth	New Jersey	07202	—
Research Facility	Plainview	New York	11803	—
Research Facility	Charlotte	North Carolina	28209	—
Research Facility	Wilmington	North Carolina	28401	—
Research Facility	Minot	North Dakota	58701	—
Research Facility	Duncansville	Pennsylvania	16635	—
Research Facility	Erie	Pennsylvania	16508	—
Research Facility	Austin	Texas	78705	—
Research Facility	Dallas	Texas	75231	—
Research Facility	Dallas	Texas	75235	—
Research Facility	San Antonio	Texas	78217	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00369928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 7, 2011 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00369928 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →